To Get Full Access :
Orlynvah is an oral tablet for adult women with uncomplicated urinary tract infections caused by E. coli, K. pneumoniae, or P. mirabilis, especially for those with limited or no alternative oral antibiotic options. It combines sulopenem (an antibiotic) with probenecid, which helps increase sulopenem levels, delivering strong antibacterial activity comparable or superior to ciprofloxacin and amoxicillin/clavulanate in clinical trials.
Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets
For full access Sign-up / Sign-in using below Methods:
By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.
